AbbVie Inc.

AbbVie Inc.

Publications

AbbVie Inc.University of Alabama Birmingham Ohio State University Harvard Medical School

Characterization of patient perception of odor severity in hidradenitis suppurativa using TARGET-DERM HS

AbbVie Inc.University of Minnesota Mount Sinai

Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry

AbbVie Inc.Mount Sinai

Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA

Novartis AG Harvard Medical School / Beth Israel Deaconess AbbVie Inc.University of Alabama Birmingham

Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS

Novartis AG Harvard Medical School / Beth Israel Deaconess AbbVie Inc.University of Alabama Birmingham

Patient reported burden is associated with clinician-reported severity in alopecia areata: Real world insights from TARGET-DERM AA

11

Total Publications

1

Oral Presentation

10

Poster Presentation

2026 · Poster Presentation · AbbVie Inc. · Dermatology

Characterization of patient perception of odor severity in hidradenitis suppurativa using TARGET-DERM HS

2025 · Poster Presentation · AbbVie Inc. · Dermatology

Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry

2025 · Poster Presentation · AbbVie Inc. · Dermatology

Generic vs. disease-specific patient reported outcome (PRO) instruments for assessing HRQoL burden among patients diagnosed with alopecia areata: Evidence from TARGET-DERM AA

2024 · Poster Presentation · Novartis AG · Dermatology

Real-world study of hidradenitis suppurativa: skin lesions and pain are associated with Hurley Stage in TARGET-DERM HS

2024 · Oral Presentation · Novartis AG · Dermatology

Patient reported burden is associated with clinician-reported severity in alopecia areata: Real world insights from TARGET-DERM AA

2024 · Poster Presentation · AbbVie Inc. · Dermatology

Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry (Fall Clinical 2024)

2024 · Poster Presentation · AbbVie Inc. · Dermatology

Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry (RAD Winter 2023)

2023 · Poster Presentation · AbbVie Inc. · Dermatology

Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from TARGET-DERM registry (RAD Winter 2023)

2022 · Poster Presentation · AbbVie Inc. · Dermatology

Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort (RAD 2021)

2022 · Poster Presentation · University of Chicago · Gastroenterology

The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn's Disease in TARGET IBD

2021 · Poster Presentation · AbbVie Inc. · Gastroenterology

Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort